Picture of Mauna Kea Technologies SA logo

ALMKT — Mauna Kea Technologies SA News Story

0.000.00%
fr flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapNeutral

Brief: Mauna Kea Cellvizio Demonstrates Superior Identification Of Patients At Risk For Esophageal Cancer

April 13 (Reuters) - MAUNA KEA TECHNOLOGIES SAS  MKEA.PA :
    * MAUNA KEA TECHNOLOGIES’ CELLVIZIO® DEMONSTRATES SUPERIOR
IDENTIFICATION OF PATIENTS AT RISK FOR ESOPHAGEAL CANCER
COMPARED TO CURRENT DIAGNOSTIC STANDARD
    * RESULTS FROM NEW CLINICAL STUDY THAT ENROLLED 172 PATIENTS
AT 8
NON-ACADEMIC CENTERS IN UNITED-STATES

Source text for Eikon:  ID:nBw4xSYLga 
Further company coverage:  MKEA.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))

Recent news on Mauna Kea Technologies SA

See all news